Cyclacel Pharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    549300IE74IVYY7IL203
    ISIN
    US23254L8019 (CYCC)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 48 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    -€21.46K
    Gross margin
    120.0%
    EBIT
    -€8.89M
    EBIT margin
    41,432.0%
    Net income
    -€5.50M
    Net margin
    25,632.0%

    Statement period: - (published )

    Dividends

    Last dividend amount
    $0.00
    Ex date
    Payment date

    Earnings Calls

    Latest earnings call: May 14, 2024

    Add to watchlist

    Notifications